RxDoctor Payments Data

David Jarosz

Family · Keystone Heights, FLNPI 1225003460

Payments from drug & device makers

$600in general payments, 2019–2025

Across 33 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$405
  • Novo Nordisk$80
  • Corcept Therapeutics$37
  • Gilead$30
  • Abbott$21
  • AstraZeneca$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$600100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie23$405
Novo Nordisk4$80
Corcept Therapeutics2$37
Gilead1$30
Abbott1$21
AstraZeneca1$15
Lilly USA, LLC1$13

How this compares

$600 in reported general payments places this provider in the 60th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$660
Medicare patients
38
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$100,674
JardianceEmpagliflozin43$56,027
XareltoRivaroxaban40$45,246
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$42,150
EntrestoSacubitril/Valsartan19$29,124
SymbicortBudesonide/Formoterol Fumarate76$26,332
JanuviaSitagliptin Phosphate16$25,511
TrulicityDulaglutide15$24,551
OzempicSemaglutide20$23,771
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$20,773
FarxigaDapagliflozin Propanediol18$20,583
Breo ElliptaFluticasone/Vilanterol38$19,147
Combivent RespimatIpratropium/Albuterol Sulfate22$18,353
VraylarCariprazine Hcl11$15,050
Tresiba Flextouch U-100Insulin Degludec34$14,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort, Farxiga$15$46,91594 claims
Novo NordiskOzempic, Levemir$80$26,58440 claims
Lilly USA, LLCTrulicity$13$24,55115 claims
AbbVieVraylar$405$15,05011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 14,618 family providers in Florida.

Other family in Keystone Heights

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →